Short conserved sequences of HIV-1 are highly immunogenic and shift immunodominance

Journal of Virology

Volumn 89, Issue 2, 2015, Pages 1195-1204

  Yang, Otto O ^a,b,c   Ali, Ayub ^a   Kasahara, Noriyuki ^a   Faure Kumar, Emmanuelle ^a   Bae, Jin Young ^d   Picker, Louis J ^d   Park, Haesun ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c AIDS HEALTHCARE FOUNDATION   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CONSERVED REGION VACCINE; DNA VACCINE; GAG PROTEIN; INFLUENZA VACCINE; NEF PROTEIN; PROTEOME; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; WHOLE PROTEIN VACCINE; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEF PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; RECOMBINANT VACCINE;

ADULT; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOGENICITY; INFLUENZA VACCINATION; NONHUMAN; RHESUS MONKEY; VIRAL GENE DELIVERY SYSTEM; ANIMAL; CONSERVED SEQUENCE; IMMUNOLOGY;

COWBONE RIDGE VIRUS; HUMAN ADENOVIRUS TYPE 5; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA MULATTA;

AIDS VACCINES; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CONSERVED SEQUENCE; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV-1; IMMUNODOMINANT EPITOPES; MACACA MULATTA; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 84920842321     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02370-14     Document Type: Article

References (44)

1. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. 1994. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 68:6103-6110.
2. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, Ho DD. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68:4650-4655.
3. Allen TM, Altfeld M, Geer SC, Kalife ET, Moore C, O'Sullivan MK, Desouza I, Feeney ME, Eldridge RL, Maier EL, Kaufmann DE, Lahaie MP, Reyor L, Tanzi G, Johnston MN, Brander C, Draenert R, Rockstroh JK, Jessen H, Rosenberg ES, Mallal SA, Walker BD. 2005. Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J Virol 79:13239-13249. http://dx.doi.org/10.1128/JVI.79.21.13239-13249.2005.
4. Liu Y, McNevin J, Cao J, Zhao H, Genowati I, Wong K, McLaughlin S, McSweyn MD, Diem K, Stevens CE, Maenza J, He H, Nickle DC, Shriner D, Holte SE, Collier AC, Corey L, McElrath MJ, Mullins JI. 2006. Selection on the human immunodeficiency virus type 1 proteome following primary infection. J Virol 80:9519-9529. http://dx.doi.org/10.1128/JVI.00575-06.
5. Moore CB, John M, James IR, Christiansen FT, Witt CS, Mallal SA. 2002. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 296:1439-1443. http://dx.doi.org/10.1126/science.1069660.
6. Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, Blanchard J, Irwin CE, Safrit JT, Mittler J, Weinberger L, Kostrikis LG, Zhang L, Perelson AS, Ho DD. 1999. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 189:991-998. http://dx.doi.org/10.1084/jem.189.6.991.
7. Matano T, Shibata R, Siemon C, Connors M, Lane HC, Martin MA. 1998. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J Virol 72:164-169.
8. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, Lifton MA, Racz P, Tenner-Racz K, Dalesandro M, Scallon BJ, Ghrayeb J, Forman MA, Montefiori DC, Rieber EP, Letvin NL, Reimann KA. 1999. Control of viremia in simian immunodeficiency virus infection by CD8+lymphocytes. Science 283:857-860. http://dx.doi.org/10.1126/science.283.5403.857.
9. Goulder PJ, Altfeld MA, Rosenberg ES, Nguyen T, Tang Y, Eldridge RL, Addo MM, He S, Mukherjee JS, Phillips MN, Bunce M, Kalams SA, Sekaly RP, Walker BD, Brander C. 2001. Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J Exp Med 193:181-194. http://dx.doi.org/10.1084/jem.193.2.181.
10. Jones NA, Wei X, Flower DR, Wong M, Michor F, Saag MS, Hahn BH, Nowak MA, Shaw GM, Borrow P. 2004. Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. J Exp Med 200:1243-1256. http://dx.doi.org/10.1084/jem.20040511.
11. Frahm N, Korber BT, Adams CM, Szinger JJ, Draenert R, Addo MM, Feeney ME, Yusim K, Sango K, Brown NV, SenGupta D, Piechocka-Trocha A, Simonis T, Marincola FM, Wurcel AG, Stone DR, Russell CJ, Adolf P, Cohen D, Roach T, St John A, Khatri A, Davis K, Mullins J, Goulder PJ, Walker BD, Brander C. 2004. Consistent cytotoxic-Tlymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J Virol 78:2187-2200. http://dx.doi.org/10.1128/JVI.78.5.2187-2200.2004.
12. Koibuchi T, Allen TM, Lichterfeld M, Mui SK, O'Sullivan KM, Trocha A, Kalams SA, Johnson RP, Walker BD. 2005. Limited sequence evolution within persistently targeted CD8 epitopes in chronic human immunodeficiency virus type 1 infection. J Virol 79:8171-8181. http://dx.doi.org/10.1128/JVI.79.13.8171-8181.2005.
13. Guadalupe M, Reay E, Sankaran S, Prindiville T, Flamm J, McNeil A, Dandekar S. 2003. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 77:11708-11717. http://dx.doi.org/10.1128/JVI.77.21.11708-11717.2003.
14. Rosenberg ES, LaRosa L, Flynn T, Robbins G, Walker BD. 1999. Characterization of HIV-1-specific T-helper cells in acute and chronic infection. Immunol Lett 66:89-93. http://dx.doi.org/10.1016/S0165-2478(98)00165-5.
15. Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GM, Papagno L, Ogg GS, King A, Lechner F, Spina CA, Little S, Havlir DV, Richman DD, Gruener N, Pape G, Waters A, Easterbrook P, Salio M, Cerundolo V, McMichael AJ, Rowland-Jones SL. 2002. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 8:379-385. http://dx.doi.org/10.1038/nm0402-379.
16. Kalams SA, Buchbinder SP, Rosenberg ES, Billingsley JM, Colbert DS, Jones NG, Shea AK, Trocha AK, Walker BD. 1999. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. J Virol 73:6715-6720.
17. Altfeld M, Addo MM, Rosenberg ES, Hecht FM, Lee PK, Vogel M, Yu XG, Draenert R, Johnston MN, Strick D, Allen TM, Feeney ME, Kahn JO, Sekaly RP, Levy JA, Rockstroh JK, Goulder PJ, Walker BD. 2003. Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. AIDS 17:2581-2591. http://dx.doi.org/10.1097/00002030-200312050-00005.
18. Streeck H, Lichterfeld M, Alter G, Meier A, Teigen N, Yassine-Diab B, Sidhu HK, Little S, Kelleher A, Routy JP, Rosenberg ES, Sekaly RP, Walker BD, Altfeld M. 2007. Recognition of a defined region within p24 gag by CD8+ T cells during primary human immunodeficiency virus type 1 infection in individuals expressing protective HLA class I alleles. J Virol 81:7725-7731. http://dx.doi.org/10.1128/JVI.00708-07.
19. Kulkarni V, Valentin A, Rosati M, Alicea C, Singh AK, Jalah R, Broderick KE, Sardesai NY, Le Gall S, Mothe B, Brander C, Rolland M, Mullins JI, Pavlakis GN, Felber BK. 2014. Altered response hierarchy and increased T-cell breadth upon HIV-1 conserved element DNA vaccination in macaques. PLoS One 9:e86254. http://dx.doi.org/10.1371/journal.pone.0086254.
20. Rosario M, Bridgeman A, Quakkelaar ED, Quigley MF, Hill BJ, Knudsen ML, Ammendola V, Ljungberg K, Borthwick N, Im EJ, McMichael AJ, Drijfhout JW, Greenaway HY, Venturi V, Douek DC, Colloca S, Liljestrom P, Nicosia A, Price DA, Melief CJ, Hanke T. 2010. Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques. Eur J Immunol 40:1973-1984. http://dx.doi.org/10.1002/eji.201040344.
21. Stephenson KE, SanMiguel A, Simmons NL, Smith K, Lewis MG, Szinger JJ, Korber B, Barouch DH. 2012. Full-length HIV-1 immunogens induce greater magnitude and comparable breadth of T lymphocyte responses to conserved HIV-1 regions compared with conserved-regiononly HIV-1 immunogens in rhesus monkeys. J Virol 86:11434-11440. http://dx.doi.org/10.1128/JVI.01779-12.
22. Yang OO. 2009. Candidate vaccine sequences to represent intra-and inter-clade HIV-1 variation. PLoS One 4:e7388. http://dx.doi.org/10.1371/journal.pone.0007388.
23. Fischer W, Perkins S, Theiler J, Bhattacharya T, Yusim K, Funkhouser R, Kuiken C, Haynes B, Letvin NL, Walker BD, Hahn BH, Korber BT. 2007. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 13:100-106. http://dx.doi.org/10.1038/nm1461.
24. Thurmond J, Yoon H, Kuiken C, Yusim K, Perkins S, Theiler J, Bhattacharya T, Korber B, Fischer W. 2008. Web-based design and evaluation of T-cell vaccine candidates. Bioinformatics 24:1639-1640. http://dx.doi.org/10.1093/bioinformatics/btn251.
25. Catanzaro AT, Roederer M, Koup RA, Bailer RT, Enama ME, Nason MC, Martin JE, Rucker S, Andrews CA, Gomez PL, Mascola JR, Nabel GJ, Graham BS. 2007. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 25:4085-4092. http://dx.doi.org/10.1016/j.vaccine.2007.02.050.
26. Graham BS, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z, Martin JE, McCluskey MM, Chakrabarti BK, Lamoreaux L, Andrews CA, Gomez PL, Mascola JR, Nabel GJ. 2006. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 194:1650-1660. http://dx.doi.org/10.1086/509259.
27. Nabel GJ, Huang Y, Xu L, Chakrabarti B, Wu L, Yang Z-Y, Gall JD, King R. 23 February 2006. Vaccines against AIDS comprising cmv/r nucleic acid constructs. US patent WO 2006020071 A2.
28. Reference deleted.
29. Reference deleted.
30. Reference deleted.
31. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.
32. Walker JM, Maecker HT, Maino VC, Picker LJ. 2004. Multicolor flow cytometric analysis in SIV-infected rhesus macaque. Methods Cell Biol 75:535-557. http://dx.doi.org/10.1016/S0091-679X(04)75022-0.
33. Wiseman RW, Karl JA, Bimber BN, O'Leary CE, Lank SM, Tuscher JJ, Detmer AM, Bouffard P, Levenkova N, Turcotte CL, Szekeres E, Jr, Wright C, Harkins T, O'Connor DH. 2009. Major histocompatibility complex genotyping with massively parallel pyrosequencing. Nat Med 15:1322-1326. http://dx.doi.org/10.1038/nm.2038.
34. Palmowski MJ, Choi EM, Hermans IF, Gilbert SC, Chen JL, Gileadi U, Salio M, Van Pel A, Man S, Bonin E, Liljestrom P, Dunbar PR, Cerundolo V. 2002. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J Immunol 168: 4391-4398. http://dx.doi.org/10.4049/jimmunol.168.9.4391.
35. Rodriguez F, Harkins S, Slifka MK, Whitton JL. 2002. Immunodominance in virus-induced CD8(+) T-cell responses is dramatically modified by DNA immunization and is regulated by gamma interferon. J Virol 76:4251-4259. http://dx.doi.org/10.1128/JVI.76.9.4251-4259.2002.
36. Kunwar P, Hawkins N, Dinges WL, Liu Y, Gabriel EE, Swan DA, Stevens CE, Maenza J, Collier AC, Mullins JI, Hertz T, Yu X, Horton H. 2013. Superior control of HIV-1 replication by CD8+ T cells targeting conserved epitopes: implications for HIV vaccine design. PLoS One 8:e64405. http://dx.doi.org/10.1371/journal.pone.0064405.
37. Mothe B, Llano A, Ibarrondo J, Daniels M, Miranda C, Zamarreno J, Bach V, Zuniga R, Perez-Alvarez S, Berger CT, Puertas MC, Martinez-Picado J, Rolland M, Farfan M, Szinger JJ, Hildebrand WH, Yang OO, Sanchez-Merino V, Brumme CJ, Brumme ZL, Heckerman D, Allen TM, Mullins JI, Gomez G, Goulder PJ, Walker BD, Gatell JM, Clotet B, Korber BT, Sanchez J, Brander C. 2011. Definition of the viral targets of protective HIV-1-specific T cell responses. J Transl Med 9:208. http://dx.doi.org/10.1186/1479-5876-9-208.
38. Rolland M, Manocheewa S, Swain JV, Lanxon-Cookson EC, Kim M, Westfall DH, Larsen BB, Gilbert PB, Mullins JI. 2013. HIV-1 conserved-element vaccines: relationship between sequence conservation and replicative capacity. J Virol 87:5461-5467. http://dx.doi.org/10.1128/JVI.03033-12.
39. Yusim K, Kesmir C, Gaschen B, Addo MM, Altfeld M, Brunak S, Chigaev A, Detours V, Korber BT. 2002. Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation. J Virol 76: 8757-8768. http://dx.doi.org/10.1128/JVI.76.17.8757-8768.2002.
40. Kawashima Y, Pfafferott K, Frater J, Matthews P, Payne R, Addo M, Gatanaga H, Fujiwara M, Hachiya A, Koizumi H, Kuse N, Oka S, Duda A, Prendergast A, Crawford H, Leslie A, Brumme Z, Brumme C, Allen T, Brander C, Kaslow R, Tang J, Hunter E, Allen S, Mulenga J, Branch S, Roach T, John M, Mallal S, Ogwu A, Shapiro R, Prado JG, Fidler S, Weber J, Pybus OG, Klenerman P, Ndung'u T, Phillips R, Heckerman D, Harrigan PR, Walker BD, Takiguchi M, Goulder P. 2009. Adaptation of HIV-1 to human leukocyte antigen class I. Nature 458:641-645. http://dx.doi.org/10.1038/nature07746.
41. Trachtenberg E, Korber B, Sollars C, Kepler TB, Hraber PT, Hayes E, Funkhouser R, Fugate M, Theiler J, Hsu YS, Kunstman K, Wu S, Phair J, Erlich H, Wolinsky S. 2003. Advantage of rare HLA supertype in HIV disease progression. Nat Med 9:928-935. http://dx.doi.org/10.1038/nm893.
42. Kraynyak KA, Kutzler MA, Cisper NJ, Khan AS, Draghia-Akli R, Sardesal NY, Lewis MG, Yan J, Weiner DB. 2010. Systemic immunization with CCL27/CTACK modulates immune responses at mucosal sites in mice and macaques. Vaccine 28:1942-1951. http://dx.doi.org/10.1016/j.vaccine.2009.10.095.
43. Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC, Drummond DD, Legasse AW, Axthelm MK, Oswald K, Trubey CM, Piatak M, Jr, Lifson JD, Nelson JA, Jarvis MA, Picker LJ. 2009. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 15: 293-299. http://dx.doi.org/10.1038/nm.1935.
44. Park H, Adamson L, Ha T, Mullen K, Hagen SI, Nogueron A, Sylwester AW, Axthelm MK, Legasse A, Piatak M, Jr, Lifson JD, McElrath JM, Picker LJ, Seder RA. 2013. Polyinosinic-polycytidylic acid is the most effective TLR adjuvant for SIV Gag protein-induced T cell responses in nonhuman primates. J Immunol 190:4103-4115. http://dx.doi.org/10.4049/jimmunol.1202958.